News
QIAGEN Launches QIAcube Connect MDx Platform for Automated Sample Processing in Diagnostic Labs
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the global launch of the QIAcube Connect MDx, a flexible platform for automated sample processing that will now be available
ABIONYX Announces Positive Clinical Results From CER-001 in the LCAT Deficiency Disease Published in the Annals of Internal Medicine
ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to innovative therapies for patients, today announces positive clinical results from CER-001 in
Navidea Biopharmaceuticals Announces $5 Million Private Placement with Existing Investor
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to
Eyenovia Announces FDA Acceptance of the MydCombi NDA
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the U.S. Food and Drug
Deciphera Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in a fireside chat at the Barclays Global Healthcare
Aurinia Pharmaceuticals to Present at Three Upcoming March Investor Conferences
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the executive management team will participate in multiple upcoming investor conferences
Transgene to Present Its Immuno-Oncology Expertise at Upcoming Scientific Conferences
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces that members of Transgene’s management
IMV to Participate at the upcoming H.C. Wainwright Global Life Sciences Conference
IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious
Transgene and BioInvent Have Enrolled First Patient in Phase I/IIa Trial of Novel Oncolytic Virus BT-001 in Solid Tumors
Regulatory News:
Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and BioInvent International AB (“BioInvent”) (Nasdaq
Puma Biotechnology und Pierre Fabre ändern die NERLYNX®-Lizenzvereinbarung, die neu auch Großchina einbezieht
Das Biopharmaunternehmen Puma Biotechnology, Inc. (Nasdaq: PBYI), und das namhafte französische Pharmaunternehmen Pierre Fabre haben eine Verlängerung der Lizenzvereinbarung von 2019 vereinbart
NANOBIOTIX 2020 Q4 and Annual Revenues
Regulatory News:
NANOBIOTIX (Euronext : NANO – NASDAQ: NBTX – the ‘‘Company’’), a clinical-stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for
European Medicines Agency Accepts Pfizer’s Marketing Authorization Application for Its Investigational 20-valent Pneumococcal Conjugate Vaccine for Adults 18 Years of Age or Older
Pfizer Inc. (NYSE:PFE) today announced that the European Medicines Agency (EMA) accepted for review the Marketing Authorization Application (MAA) for its 20-valent pneumococcal conjugate vaccine
EMA Accepts Marketing Application for Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency
Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the European Medicines Agency (EMA) has validated for review the Marketing Authorization Application (MAA) for
Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2020. Unless otherwise stated, all comparisons
Puma Biotechnology and Pierre Fabre Amend NERLYNX® License Agreement to Include Greater China
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, and Pierre Fabre, a leading French pharmaceutical company, have agreed to extend the terms of the 2019 license agreement which
Aimmune Presents New Clinical Data From Pooled Safety Analysis in Patients Treated With PALFORZIA® for up to ~3.5 Years
Aimmune Therapeutics, a Nestlé Health Science company developing and commercializing treatments for potentially life-threatening food allergies, today announced new clinical data from a pooled
Charles River Laboratories Announces Strategic Partnership with Kibur Medical to Advance Preclinical Oncology Studies
Charles River Laboratories International, Inc. (NYSE: CRL) today announced a strategic partnership with Kibur Medical to offer exclusive access to its implantable microdevice (IMD) for in vivo
Pfizer and BioNTech Initiate a Study as Part of Broad Development Plan to Evaluate COVID-19 Booster and New Vaccine Variants
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today they have begun an evaluation of the safety and immunogenicity of a third dose of the Pfizer-BioNTech COVID-19 vaccine
Novocure Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Company Update
Novocure (NASDAQ: NVCR) today reported financial results for the quarter and full year ended December 31, 2020, highlighting revenue growth and financial strength as well as the advancement of the
Xencor and UCLA Enter Collaboration to Discover and Develop Novel XmAb® Therapeutics
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, and UCLA
Genus plc Reports Interim First Half 2021 Fiscal Year Results
Genus plc (LSE: GNS), a global biotechnology leader in animal genetics, today reported interim results for the six-months period ending December 31, 2020, as well as provided a business update on
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported fourth quarter and full year 2020 financial results and recent business highlights.
“We are very pleased with
Aurinia Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Operational Highlights
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”) today issued its financial results for the fourth quarter and year ended December 31, 2020. Amounts, unless
ICON to Acquire PRA Health Sciences, Creating a World Leader in Healthcare Intelligence and Clinical Research
ICON plc, (NASDAQ: ICLR), a global provider of outsourced drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, and